Skip to content

Contact +44 (0) 20 7060 7474 email us

Drug Discovery

Drug Discovery in India and China

Gaining Momentum with Increasing Pressure on Cost Cutting

Publication Date February 2010
Publisher GBI Research
Product Type Report
Pages 107
ISBN Number not applicable
Product Code GBI00024

Price

£2,310.00
approximately: $3,498 | €2,578

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

GBI Research, the leading business intelligence provider, has released its latest report, "Drug Discovery in India and China - Gaining Momentum with Increasing Pressure on Cost Cutting." It provides key data, information and analysis of the major trends and issues affecting the drug discovery market in India and China. The report provides a comprehensive insight into the drug discovery process and the model followed by the companies providing such services. The report also provides a detailed analysis of the factors that are driving the drug discovery market, a key segment of the pharmaceutical and healthcare industry, in India and China. The report talks about the key regulations, especially with respect to intellectual property rights protection, and how these regulations have benefited drug discovery companies in these two nations. The study analyses key partnerships between the local companies in the two countries and their western counterparts and the key trends emerging out of such partnerships. It also provides an insight into the government support initiatives in these countries to encourage the drug discovery research. This research provides a comparative analysis of the two countries and the major differences between India and China when it comes to drug discovery.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes:

  • Study of major discovery research services including medicinal chemistry, Drug Metabolism and Pharmacokinetics (DMPK), pharmacology and toxicology offered by the Indian and the Chinese drug discovery companies
  • Analysis of major therapeutic areas under drug discovery research such as oncology, inflammatory diseases and metabolic diseases
  • Study of key Indian and Chinese drug discovery players such as Aurigene, Syngene, WuXi and Shanghai ChemPartner, and their deals/partnerships with western pharma companies
  • Analysis of key intellectual property regulations and government support in India and China affecting the drug discovery market
  • Analysis of the key drivers that are fueling the growth of the drug discovery market in India and China and future outlook of the drug discovery market in India and China

Reasons to buy

The report will enhance your decision making and will enable you to:

  • Optimize your discovery research outsourcing through identification of major service capabilities of the Indian and Chinese drug discovery companies
  • Develop market entry and market expansion strategies by identifying the key drivers and restraints in the Indian and Chinese drug discovery market
  • Identify the key therapeutic areas in which Indian and Chinese drug discovery companies have major capabilities
  • Build a strong presence in the Indian and Chinese drug discovery market through identification of key local players for partnerships and their competencies
  • Compare both the countries to identify the geography that could provide maximum capability improvement to your discovery research
  • Plan better strategies to protect your intellectual property in these countries
  • Enhance and frame better marketing strategies through an understanding of the regulatory environment in these countries

Contents

  • 1 Table of contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction
    • 2.1 GBI Research Report Guidance
  • 3 Drug Discovery Process - Overview
    • 3.1 Process of Early Preclinical Drug Discovery
      • 3.1.1 Pre-discovery
      • 3.1.2 Target Identification
      • 3.1.3 Target Validation
      • 3.1.4 Lead Identification
      • 3.1.5 Early Safety Tests
      • 3.1.6 Lead Optimization
      • 3.1.7 Preclinical Testing
    • 3.2 Major Services under Drug Discovery Stage
      • 3.2.1 Medicinal Chemistry
      • 3.2.2 Pharmacology
      • 3.2.3 HTS (High-throughput Screening)
      • 3.2.4 Analytical Chemistry
      • 3.2.5 CADD (Computer Aided Drug Design)
    • 3.3 Conclusion
  • 4 Drug Discovery in India and China - Market Characteristics
    • 4.1 Drug Discovery Market Characterization
      • 4.1.1 Market Share & Market Size
      • 4.1.2 Top 5 Services Offered by Indian and Chinese Players
      • 4.1.3 Major Therapeutic Areas under Research
    • 4.2 Forces that Drive Drug Discovery in India and China
      • 4.2.1 Declining R&D Productivity, Especially For the Big Pharma
      • 4.2.2 Generics Competition - Pricing Pressures on Branded Prescription Products
      • 4.2.3 Stringent Regulatory Conditions and Increasing Patent Challenges Lead to Shorter Product Lifecycles
      • 4.2.4 Removing Redundancies - Focusing on Core Competencies
    • 4.3 Why India and China?
      • 4.3.1 Availability of Skilled Manpower
      • 4.3.2 Scale of Available Resources for Clinical Development
      • 4.3.3 Improved IP Protection in India and China
      • 4.3.4 Government Support for the Drug Discovery Development
      • 4.3.5 Risk Sharing Agreements: A Step Forward by Indian and Chinese Companies
    • 4.4 SWOT Analysis
    • 4.5 Conclusion
  • 5 IP Protection in India and China - Improved IP Protection to Encourage Innovation
    • 5.1 India
      • 5.1.1 Patent Act 2005 - First Step towards Improving IP Protection
      • 5.1.2 IPR Enforcement Rules, 2007
      • 5.1.3 Trademarks Bill 2007
      • 5.1.4 Drugs and Cosmetics Act (Amendment) 2008
      • 5.1.5 EIPR (Enforcers of Intellectual Property Rights) - Ensuring IPR Laws Implementation in India
      • 5.1.6 Case 1: BMS (Bristol-Myers Squibb) versus Hetero Drugs on Dasatinib
      • 5.1.7 Case 2: Bayer versus Cipla on Nexavar
      • 5.1.8 Case 3: Roche versus Cipla on Tarceva
      • 5.1.9 Key Takeaways
    • 5.2 China
      • 5.2.1 Trademark Law
      • 5.2.2 Patent Law
      • 5.2.3 Anti-Unfair Competition Law
      • 5.2.4 Regulations on Customs Protection of Intellectual Property Rights
      • 5.2.5 Case 1: Pfizer versus PRB on Viagra
      • 5.2.6 Case 2: Aida Pharmaceuticals versus Four Counterfeit Suppliers
      • 5.2.7 Case 3: Pfizer versus Guangzhou Welman on Viagra Trademark: Lethargy Proves Costly to Pfizer
      • 5.2.8 Key Takeaways
  • 6 Government and Regulatory Support in India and China - Strong Support to Research Institutes and Small Companies
    • 6.1 Government/Regulatory Support for Drug Discovery in India
      • 6.1.1 Open Source Drug Discovery
      • 6.1.2 Drug Development Promotion Board: Encouraging PPP Model for Drug Discovery and Development
      • 6.1.3 Technology Development Board: Supporting Technology Oriented Projects
      • 6.1.4 NMITLI (New Millennium Indian Technology Leadership Initiative) Scheme
    • 6.2 Government/Regulatory Support for Drug Discovery in China
      • 6.2.1 Setting Up of Biotech Parks in Shanghai and Beijing -Zhangjiang High-Tech Park
      • 6.2.2 Research Institutes - Shanghai Institute of Materia Medica
      • 6.2.3 National Center for Drug Screening
      • 6.2.4 International TCM Program for Cooperation in Science & Technology
    • 6.3 Conclusion
  • 7 Major Indian and Chinese Drug Discovery Companies - Different Business Models to Provide Similar Services
    • 7.1 Indian and Chinese Drug Discovery Companies - Business Models
      • 7.1.1 Indian Drug Discovery Business Model - R&D Hive-off for Better Services and Risk Reduction
      • 7.1.2 Chinese Drug Discovery Business Model - Drug Discovery and Development as Core Business
    • 7.2 Jubilant Organosys' Jubilant Biosys
      • 7.2.1 About Jubilant Organosys
      • 7.2.2 Jubilant Biosys
      • 7.2.3 Major Drug Discovery Deals
    • 7.3 Dr. Reddy's Aurigene
      • 7.3.1 About Dr. Reddy's
      • 7.3.2 Aurigene
      • 7.3.3 Major Drug Discovery Deals
    • 7.4 Biocon's Syngene
      • 7.4.1 About Biocon
      • 7.4.2 Syngene
      • 7.4.3 Major Drug Discovery Deals
    • 7.5 GVK BIO
      • 7.5.1 Business Description
      • 7.5.2 Major Drug Discovery Deals
    • 7.6 Advinus Therapeutics
      • 7.6.1 Business Description
      • 7.6.2 Major Drug Discovery Deals
    • 7.7 WuXi AppTec
      • 7.7.1 Business Description
      • 7.7.2 Major Drug Discovery Deals
    • 7.8 Chi-Med's Hutchison MediPharma
      • 7.8.1 About Chi-Med
      • 7.8.2 Hutchison MediPharma
      • 7.8.3 Major Drug Discovery Deals
    • 7.9 Shanghai ChemPartner
      • 7.9.1 Business Description
      • 7.9.2 Major Drug Discovery Deals
    • 7.10 HD BioSciences
      • 7.10.1 Business Description
      • 7.10.2 Major Drug Discovery Deals
    • 7.11 Sundia MediTech
      • 7.11.1 Business Description
      • 7.11.2 Major Drug Discovery Deals
  • 8 Deals Analysis - Equal Thrust From Big Pharma and Mid-Size Pharma
    • 8.1 Number of Discovery Research Deals - Increased Activity by Big and Mid-size Pharma
    • 8.2 Deals by Major Therapeutic Area - Oncology and Metabolic Disorders
    • 8.3 Deals by Client Type - Mid-size Pharma Deals Rising in India and China
    • 8.4 Major Drug Discovery Deals
      • 8.4.1 Amgen with Jubilant Biosys: Supporting Early Stage Preclinical Development Effort to Provide Cost-Effective Drugs
      • 8.4.2 Bristol-Myers Squibb with Syngene: Dedicated Research Facility for Discovery and Early Drug Development
      • 8.4.3 AstraZeneca with WuXi: Delivering Value beyond Just Cost-Savings
      • 8.4.4 Genzyme Corporation and MMV (Medicines for Malaria Venture) with Advinus Therapeutics: To Address the Unmet Needs of Neglected Diseases in Developing Countries
      • 8.4.5 Xcovery with Sundia MediTech: Exemplifies 100% Outsourcing as the Most Efficient and Economical Model for New Drug Discovery
      • 8.4.6 Novartis with Aurigene: Generating Pre-clinical Candidates for Oncology-focused Program
      • 8.4.7 Merck & Co with Advinus Therapeutics: To Develop Clinically Validated Drug Candidates for Metabolic Disorders
      • 8.4.8 Eli Lilly with Hutchison MediPharma: Developing Innovative Medicine for Global Market
      • 8.4.9 Pfizer with HD BioSciences: To Provide Quality Biology Discovery Services
      • 8.4.10 LEAD Therapeutics with Shanghai ChemPartner: Accelerating Drug Discovery Efforts to Generate Novel and Differentiated pre-IND Candidates
    • 8.5 Conclusion
  • 9 Future Challenges- Financial and Intellectual Obstacles to Impede the Future Growth
    • 9.1 Financial Problems will Make It Difficult to Sustain the Growth
    • 9.2 Talent Shortage in Early Stage Chemistry and Biology
    • 9.3 Competition from Europe as an Alternative Discovery Research Destination
    • 9.4 Conclusion
  • 10 Key Takeaway
  • 11 Appendix
    • 11.1 Market Definitions
    • 11.2 Abbreviations
    • 11.3 Research Methodology
      • 11.3.1 Coverage
      • 11.3.2 Secondary Research
      • 11.3.3 Primary Research
      • 11.3.4 Expert Panel Validation
    • 11.4 Contact Us
    • 11.5 Disclaimer
    • 11.6 Sources
  • 1.1 List of Tables
    • Table 1: Drug Discovery Market, India and China, Historic Market Size, $bn, 2004-2009
    • Table 2: Drug Discovery Market, India and China, Market Size Forecast, $bn, 2009-2016
    • Table 3: Major Services Offered by Indian and Chinese Drug Discovery Companies
    • Table 4: Key Service Offerings of Indian and Chinese Companies in Medicinal Chemistry
    • Table 5: Key Service Offerings of Indian and Chinese Companies in Drug Metabolism and Pharmacokinetics
    • Table 6: Key Service Offerings of Indian and Chinese Companies in Toxicology
    • Table 7: Key Service Offerings of Indian and Chinese Companies in Pharmacology
    • Table 8: Key Service Offerings of Indian and Chinese Companies in Molecular Biology
    • Table 9: Major Therapeutic Areas of Drug Discovery Research in India and China
    • Table 10: Major Activities of Indian and Chinese Drug Discovery Companies in Inflammatory Diseases
    • Table 11: Major Activities of Indian and Chinese Drug Discovery Companies in Metabolic Disorders
    • Table 12: Major Activities of Indian and Chinese Drug Discovery Companies in Oncology
    • Table 13: Price Difference Between Brand Name Drugs (Average Wholesale Price) and Generic Drugs, $, August 2008
    • Table 14: SWOT Analysis - Drug Discovery Market in India and China
    • Table 15: Jubilant Biosys - Major Capabilities
    • Table 16: Major Drug Discovery Deals - Jubilant Biosys
    • Table 17: Aurigene - Major Capabilities
    • Table 18: Major Drug Discovery Deals - Aurigene
    • Table 19: Syngene - Major Capabilities
    • Table 20: Major Drug Discovery Deals - Syngene
    • Table 21: GVK BIO - Major Capabilities
    • Table 22: Major Drug Discovery Deals - GVK BIO
    • Table 23: Advinus Therapeutics - Major Capabilities
    • Table 24: Major Drug Discovery Deals - Advinus Therapeutics
    • Table 25: WuXi AppTec - Major Capabilities
    • Table 26: Major Drug Discovery Deals - WuXi AppTec
    • Table 27: Hutchison MediPharma - Major Capabilities
    • Table 28: Major Drug Discovery Deals - Hutchison MediPharma
    • Table 29: Shanghai ChemPartner - Major Capabilities
    • Table 30: Major Drug Discovery Deals - Shanghai ChemPartner
    • Table 31: HD BioSciences - Major Capabilities
    • Table 32: Major Drug Discovery Deals - HD BioSciences
    • Table 33: Sundia MediTech - Major Capabilities
    • Table 34: Major Drug Discovery Deals - Sundia MediTech
  • 1.2 List of Figures
    • Figure 1: Drug Discovery Research in R&D Value Chain
    • Figure 2: Drug Discovery Process
    • Figure 3: Drug Discovery Market, India and China, Market Size, $bn, 2004-2016
    • Figure 4: Global Drug Discovery Market, Market Breakdown by Value, 2008
    • Figure 5: Comparison of CAGR of R&D Expenditure versus Turnover for the Top 5 Pharma Companies, 2004-2008
    • Figure 6: Increasing Cost of Introducing a NME in the US
    • Figure 7: Price Difference Between Brand Name Drugs (Average Wholesale Price) and Generic Drugs, $, August 2008
    • Figure 8: Savings Generated by Use of Generic Drugs During First Decade of Hatch-Waxman Act, $bn, 1999-2008
    • Figure 9: Results Breakdown of Patent Challenges, the US, 2001-2008
    • Figure 10: India & China Talent Pool - Comparison
    • Figure 11: Top 5 Nationalities of Foreign Inventors Named in the PCT (Patent Cooperation Treaty) International Applications Filed, 2008
    • Figure 12: Risk-Sharing Model Between Western Pharma Companies and Indian/Chinese Companies
    • Figure 13: Number of Patent Applications Originating from China and India, 2004-2008
    • Figure 14: Intellectual Property Rights Protection Framework in India
    • Figure 15: Intellectual Property Rights Protection Framework in China
    • Figure 16: Open Source Drug Discovery Activity Map
    • Figure 17: Technology Development Board Financial Assistance, India, Value Breakdown by Sector, 1997-2007
    • Figure 18: Comparison of Business Models, Indian and Chinese Drug Discovery Companies
    • Figure 19: Jubilant - Corporate Profile
    • Figure 20: Dr. Reddy's - Corporate Profile
    • Figure 21: Biocon - Corporate Profile
    • Figure 22: GVK BIO - Corporate Profile
    • Figure 23: Advinus Therapeutics - Corporate Profile
    • Figure 24: WuXi AppTec - Corporate Profile
    • Figure 25: Hutchison MediPharma - Corporate Profile
    • Figure 26: Shanghai ChemPartner - Corporate Profile
    • Figure 27: HD BioSciences - Corporate Profile
    • Figure 28: Sundia MediTech - Corporate Profile
    • Figure 29: Number of Major Discovery Research Deals by Country, India and China, 2006-2009
    • Figure 30: Percentage of Major Discovery Research Deals by Therapeutic Area, India and China, 2006-2009
    • Figure 31: Number of Major Discovery Research Deals in India and China by Client Company Type, 2006-2009
    • Figure 32: Major Discovery Research Deals by the Type of Client Companies for 10 Major Indian and Chinese Discovery Research Companies, 2006-2009
    • Figure 33: Top 5 Big Pharma Companies by Number of Deals in India and China, 2006-2009
    • Figure 34: Client Testimonial - BMS-Syngene Partnership
    • Figure 35: Client Testimonial - WuXi-AstraZeneca Partnership
    • Figure 36: Client Testimonial - Sundia MediTech-Xcovery Partnership
    • Figure 37: Client Testimonial - Shanghai ChemPartner-LEAD Therapeutics Partnership
    • Figure 38: Arthur Higgins, President of EFPIA on Establishing Europe as a Leading Developer of Medicines
    • Figure 39: GBI Research Methodology